Social dysfunction and default mode network functional integrity in neuropsychiatric disorders: A cross-disorder replication and generalization study
Cross-disorder research and replication of neuroimaging findings remains scarce. Social dysfunction is an early manifestation across diverse neuropsychiatric disorders that may relate to altered default mode network (DMN) integrity. This study aimed to replicate previous findings linking social dysfunction with diminished resting-state DMN functional connectivity and altered task-based DMN functional activation in response to emotional faces across schizophrenia (SZ), Alzheimer's disease (AD), and healthy controls (HC), and to extend these findings to major depressive disorder (MDD). Resting-state fMRI and task-based fMRI data on implicit facial emotional processing were acquired in an overlapping cohort (resting-state fMRI: N=167; SZ=32, MDD=44, AD=29, HC=62. Task-based fMRI: N=152; SZ=30, MDD=42, AD=26, HC=54). Additionally, mega-analyses (N=317 for resting-state fMRI; N=291 for task-based fMRI) of the current and a prior independent sample were conducted. Social dysfunction was indexed with the Social Functioning Scale (SFS) and the De Jong-Gierveld Loneliness (LON) scale. The association between higher mean SFS+LON social dysfunction scores and diminished DMN connectivity within the dorsomedial prefrontal cortex across SZ/AD/HC participants was replicated, and extended to MDD patients. Similar observations within the dorsomedial and rostromedial prefrontal cortex were found in the mega-analysis. Associations between social dysfunction and DMN activation in response to sad and happy faces were not replicated or found in the mega-analysis. To conclude, diminished dorsomedial prefrontal cortex DMN connectivity emerged as a transdiagnostic neurobiological marker for social dysfunction, suggesting a potential treatment target for precision medicine approaches. DMN functional responses to emotional faces may not be a sensitive biomarker for social dysfunction.
Authors
- Tanja Su (ORCID: https://orcid.org/0000-0001-7982-0391)
- Javier-David López-Moríñigo (ORCID: https://orcid.org/0000-0002-4264-2664)
- Geor Bakker (ORCID: https://orcid.org/0000-0002-5998-9322)
- Hugh Marston (ORCID: https://orcid.org/0000-0002-7460-0581)
- Abigail B. Abrahams (ORCID: https://orcid.org/0000-0002-9480-3909)
- Simon Braak (ORCID: https://orcid.org/0000-0002-2156-0862)
- Maarten Mennes (ORCID: https://orcid.org/0000-0002-7279-3439)
- Gerard R. Dawson (ORCID: https://orcid.org/0000-0002-8624-7500)
- ANA ORTIZ-TALLO MOYA
- Amy Christine Beckenstrom
- Nic van der Wee
- Christian F. Beckmann
- Celso Arango
- Martien J.H. Kas (ORCID: https://orcid.org/0000-0002-4471-8618)
- Brenda W.J.H. Penninx (ORCID: https://orcid.org/0000-0001-7779-9672)
- Stéphanie Bauduin
- Yolande Pijnenburg
Institutions
- Boehringer Ingelheim (Germany) (DE)
- Radboud University Nijmegen (NL)
- University of Groningen (NL)
- Leiden University Medical Center (NL)
- Hospital Universitario La Paz (ES)
- HR Wallingford (GB)
- Hospital General Universitario Gregorio Marañón (ES)
- Centro de Investigación Biomédica en Red de Salud Mental (ES)
- Amsterdam Neuroscience (NL)
- Scientific Consulting Group (US)
- Amsterdam University Medical Centers (NL)
- Universidad Autónoma de Madrid (ES)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- European Neuropsychopharmacology
- Published
- 2026-04-26
- DOI
- https://doi.org/10.1016/j.euroneuro.2026.112847
- Primary Topic
- Functional Brain Connectivity Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Federation of Pharmaceutical Industries and Associations
- Innovative Health Initiative
- Innovative Medicines Initiative
- Horizon 2020 Framework Programme